ABBVIE
A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 43
- Registration Number
- NCT04837482
- Locations
- 🇦🇺
School of Optometry and Vision Science, Queensland University of Technology /ID# 226378, Brisbane, Queensland, Australia
RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)
- Conditions
- Interventions
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT04832724
- Locations
- 🇺🇸
Wilmer Eye Institute, Baltimore, Maryland, United States
🇺🇸Retina Consultants of Texas, The Woodlands, Texas, United States
🇺🇸California Retina Consultants, Santa Barbara, California, United States
Expanded Access to Telisotuzumab Vedotin
- Conditions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- AbbVie
- Registration Number
- NCT04830202
- Locations
- 🇺🇸
Oncology & Hematology Specialist /ID# 248083, Mountain Lakes, New Jersey, United States
🇺🇸Sutter Medical Group /ID# 254816, Sacramento, California, United States
🇦🇺Western Heamatology and Oncology Clinics /ID# 243364, West Perth, Western Australia, Australia
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)
- Conditions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 600
- Registration Number
- NCT04826523
- Locations
- 🇰🇷
Kosin University Gospel Hospital /ID# 257399, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷Gachon University Gil Medical Center /ID# 239008, Incheon, Gyeonggido, Korea, Republic of
🇰🇷Kyungpook National University Hospital /ID# 257398, 중구, Daegu Gwang Yeogsi, Korea, Republic of
Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
- Conditions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 240
- Registration Number
- NCT04818385
- Locations
- 🇨🇳
National Taiwan University Hospital - Hsinchu branch /ID# 238432, Hsinchu City, Taiwan
🇨🇳Hualien Tzu Chi Hospital /ID# 238431, Hualien City, Taiwan
🇨🇳National Taiwan University Hospital /ID# 230017, Taipei City, Taiwan
Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 26
- Registration Number
- NCT04818515
- Locations
- 🇺🇸
PPD Clinical Research Unit /ID# 227676, Orlando, Florida, United States
🇺🇸Bio-Kinetic Clinical Applications, LLC /ID# 227675, Springfield, Missouri, United States
🇺🇸Spaulding Clinical Research LLC /ID# 229505, West Bend, Wisconsin, United States
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 424
- Registration Number
- NCT04813263
- Locations
- 🇯🇵
Odate Municipal General Hospital /ID# 258238, Odate-shi, Akita, Japan
🇯🇵Yokohama City University Medical Center /ID# 248777, Yokohama shi, Kanagawa, Japan
🇯🇵Kyoto University Hospital /ID# 244844, Kyoto-shi, Kyoto, Japan
Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT04810598
- Locations
- 🇺🇸
Orlando Clinical Research Ctr /ID# 224922, Orlando, Florida, United States
🇺🇸Acpru /Id# 243398, Grayslake, Illinois, United States
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis
- Conditions
- Interventions
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 40
- Registration Number
- NCT04807972
- Locations
- 🇺🇸
Johns Hopkins Hospital /ID# 226713, Baltimore, Maryland, United States
🇮🇱The Chaim Sheba Medical Center /ID# 226812, Ramat Gan, Tel-Aviv, Israel
🇮🇱Rambam Health Care Campus /ID# 229555, Haifa, H_efa, Israel
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 5
- Registration Number
- NCT04804254
- Locations
- 🇮🇱
The Chaim Sheba Medical Center /ID# 226754, Ramat Gan, Tel-Aviv, Israel
🇵🇷Hospital del Centro Comprensivo de Cancer de la UPR /ID# 225646, San Juan, Puerto Rico
🇹🇷Dokuz Eylul University Medical Faculty /ID# 226085, Izmir, Turkey